title: Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.
abstract: Nonsteroidal anti-inflammatory drugs (NSAID) such as sulindac sulfide (SS) display promising antineoplastic properties, but toxicities resulting from COX inhibition limit their clinical use. Although COX inhibition is responsible for the anti-inflammatory activity of SS, recent studies suggest that phosphodiesterase (PDE) 5 inhibition and activation of cyclic guanosine monophosphate (cGMP) signaling are closely associated with its ability to induce apoptosis of tumor cells. However, the underlying mechanisms responsible for apoptosis induction, factors that influence sensitivity of tumor cells to SS, and the importance of PDE5 for breast tumor cell growth have not been established. Here we show that SS can induce apoptosis of breast tumor cells, which predominantly rely on PDE5 for cGMP hydrolysis but not normal mammary epithelial cells, which rely on PDE isozymes other than PDE5 for cGMP hydrolysis. Inhibition of PDE5 and activation of protein kinase G (PKG) by SS was associated with increased β-catenin phosphorylation, decreased β-catenin mRNA and protein levels, reduced β-catenin nuclear localization, decreased T-cell factor/lymphoid enhancer factor (Tcf/Lef) promoter activity, and decreased expression of Wnt/β-catenin-regulated proteins. Suppression of PDE5 with siRNA or known PDE5 inhibitors was sufficient to selectively induce apoptosis and attenuate β-catenin-mediated transcription in breast tumor cells with minimal effects on normal mammary epithelial cells. These findings provide evidence that SS induces apoptosis of breast tumor cells through a mechanism involving inhibition of PDE5 and attenuation of oncogenic Wnt/β-catenin-mediated transcription. We conclude that PDE5 represents a novel molecular target for the discovery of safer and more efficacious drugs for breast cancer chemoprevention.
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, USA
authors.forename: Heather N
authors.initials: HN
authors.lastname: Tinsley
authors.forename: Bernard D
authors.initials: BD
authors.lastname: Gary
authors.forename: Adam B
authors.initials: AB
authors.lastname: Keeton
authors.forename: Wenyan
authors.initials: W
authors.lastname: Lu
authors.forename: Yonghe
authors.initials: Y
authors.lastname: Li
authors.forename: Gary A
authors.initials: GA
authors.lastname: Piazza
mesh_terms: D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D007527:Isoenzymes; D009857:Oncogenes; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction; D013467:Sulindac / Q000031:analogs & derivatives* / Q000494:pharmacology; D014158:Transcription, Genetic; D051153:Wnt Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051176:beta Catenin / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D007527:Isoenzymes; D058986:Phosphodiesterase 5 Inhibitors; D051153:Wnt Proteins; D051176:beta Catenin; D013467:Sulindac; C025462:sulindac sulfide; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006152:Cyclic GMP